

SPEAKERS

EXTERNAL SPEAKERS

Prof. Dr. Paolo Corradini, Universität Mailand
PD Dr. Christoph Lutz,
Praxis für Hämatologie und Onkologie, Koblenz
Prof. Dr. Uwe Martens, SLK-Kliniken Heilbronn
Prof. Dr. Marcela Maus, Harvard Medical School
Prof. Dr. Kai Neben, Klinikum Mittelbaden
Dr. Andrea Schmidts, TU München

INTERNAL SPEAKERS

Medizinische Klinik V (Hämatologie, Onkologie und Rheumatologie), Universitätsklinikum Heidelberg
Dr. Dr. Franziska Blaeschke
Prof. Dr. Peter Dreger
Dr. Mirco Friedrich
Prof. Dr. Anthony D. Ho
PD Dr. Tobias Kessler
Dr. Felix Korell
Prof. Dr. Thomas Luft
Prof. Dr. Hanns-Martin Lorenz
Prof. Dr. Carsten Müller-Tidow
Prof. Dr. Marc Raab
Dr. Tim Sauer
Prof. Dr. Anita Schmitt
Prof. Dr. Michael Schmitt
Prof. Dr. Stefan Schönland
Dr. Maria-Luisa Schubert
Dr. Christian Seitz
Prof. Dr. Guy Ungerechts
PD Dr. Niels Weinhold
Dr. Laura Wienecke

SPONSORS

PLATINUM

Gilead Sciences GmbH	€ 22.000
Janssen-Cilag GmbH	€ 22.000
Pierre Fabre Pharma GmbH	€ 20.000
Bristol-Myers Squibb GmbH & Co. KGaA	€ 10.000

SILVER

Mallinckrodt Pharmaceuticals Therakos (UK) Ltd.	€ 2.000
Miltenyi Biotec B.V. & Co. KG	€ 2.000
Roche Pharma AG	€ 2.000

BRONZE

Novartis Pharma GmbH	€ 1.500
Takeda Pharma Vertrieb GmbH & Co. KG	€ 1.500
Terumo Blood and Cell Technologies	€ 1.000
Lilly Deutschland GmbH	€ 1.000
Medac Gesellschaft für klinische Spezialpräparate m.b.H.	€ 1.000
MSD Sharp & Dohme GmbH	€ 1.000
Servier Deutschland GmbH	€ 1.000

VENUE

Medical Clinic
Im Neuenheimer Feld 410
69120 Heidelberg

CONTACT

Marion Mohmand
Secretary to Prof. Michael Schmitt
Universitätsklinikum Heidelberg
Medizinische Klinik V | Zelluläre Immuntherapie
Im Neuenheimer Feld 410 | 69120 Heidelberg

Phone.: 06221 56-7989
E-Mail: marion.mohmand@med.uni-heidelberg.de

Kindly relay your scientific abstracts to:

Marcel Pichal, M.A.
marcel.pichal@med.uni-heidelberg.de

REGISTER

To safeguard a proper organization of this conference, we ask participants to register through the following portal by 14 October 2024 — at the latest:

JOIN US HERE:
WWW.UKHD.DE/CELLTHERAPYSYMPOSIUM



UNIVERSITÄTS
KLINIKUM
HEIDELBERG



8th CELL-THERAPY SYMPOSIUM

NOVEMBER 15 & 16, 2024

Medical Clinic, Grand Auditorium
Im Neuenheimer Feld 410
69120 Heidelberg

Department of Medicine V
(Hematology, Oncology and Rheumatology)



DEAR COLLEAGUES,

A year has passed since the last *Cell-Therapy Symposium* took place. Within this brief period of time, tremendous progress has been made at our clinic with view to CAR-T cell therapy: More than 250 patients have received this leading-edge treatment at our medical center.

Across the globe, more than 42,000 patients have undergone remarkably successful treatment regimens for acute leukemia, Non-Hodgkin's lymphoma, as well as for myeloma. In light of this substantial track record, current therapeutic algorithms applied to tackle these diseases need to be revisited.

This symposium is meant to put special emphasis on an in-depth comparison of bispecific antibodies and CAR-T cells; in conjunction with a survey of novel TCR-T cell therapies directed at solid tumors.

Both the ongoing exploration and identification of novel targets, as well as the preclinical research necessary to further the development of immunogenic therapies will be themes of our scientific discussion.

We cordially invite all participating physicians, scientists and doctoral fellows to submit their respective abstracts, which will subsequently be presented as posters in the course of this two-day conference. Authors whose posters are deemed best, will be given the opportunity to elucidate their work in the form of a short presentation.

We are looking forward to welcoming you to our symposium.

With very warm regards from Heidelberg



Michael Schmitt Carsten Müller-Tidow Peter Dreger

The participation is free of charge.

This conference is certified by the
Landesärztekammer Baden-Württemberg.

Corresponding CME-credits are granted.

PROGRAMM

FRIDAY, 15.11.2024 SCIENTIFIC SYMPOSIUM — PART 1

13:00 **Registration, lunch and beverages**
Get-together

13:30 **Welcome address**
C. Müller-Tidow

Multiple myeloma
Chairs: M. Schmitt/A.D. Ho

13:40 **CARs and BITEs in myeloma:
Eligibility and toxicity: Points to
consider**
M. Raab

14:00 **CAR T-cell therapy for patients with
amyloidosis**
S. Schönland

14:20 **CAR-TEAMS for glioblastoma and
beyond**
M. Maus

15:00 - 16:30 **Satellite Symposium**
Fa. Kite-Gilead

16:30 **Coffee break**

Lymphoma
Chairs: P. Dreger/U. Martens/C. Lutz

17:00 **CAR T-cell therapy in uncommon
lymphomas (PMBCL, Richter,
Waldenström and CNS lymphomas)**
P. Corradini

17:30 **How to make the CAR-journey
pleasant for patients and physi-
cians: An INTEGRATED approach**
K. Neben/M.-L. Schubert

18:00 - 19:30 **Satellite Symposium**
Fa. Janssen-Cilag

SATURDAY, 16.11.2024 SCIENTIFIC SYMPOSIUM — PART 2

08:30 **Registration, snacks and beverages**
Get-together

Making CARs Better
Chairs: A. Schmitt/T. Luft

09:00 **HD-CAR-1 trial, CD39 as a novel
biomarker**
M. Schmitt

09:20 **TME-Reprogramming to improve
CAR T-cell function in solid cancers**
C. Seitz

09:40 **Breaking resistance to modern
cellular immunotherapies in
myeloma**
N. Weinhold

10:00 **Solid tumors: Cell therapies and
beyond**
G. Ungerechts

10:20 **Best Abstracts
Best Posters**

10:40 **Coffee Break**

11:00 - 12:30 **Satellite Symposium**
PTLD symposium

12:30 **Lunch Break**

Advancing CAR T-Cell Therapy
Chairs: H.M. Lorenz/T. Sauer

13:30 **CAR T-cells for brain tumors**
T. Kessler

13:50 **CAR T-cells in rheumatology**
H.M. Lorenz

14:10 **CAR T-cells in cardiology**
L. Wienecke

14:30 **Modular pooled knock-in screens:
Reprogramming therapeutic T-cells**
F. Blaeschke

14:50 **NK-cells and T-cells — not always
brothers in peace**
M. Friedrich

15:10 **Cell-based artificial APCs for
better CAR T-cell responses**
A. Schmidts

15:30 **EASIX and CAR T-cells**
F. Korell

15:50 **Closing Remarks**
M. Schmitt/P. Dreger